Compare WBX & GRML Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | WBX | GRML |
|---|---|---|
| Founded | 2015 | N/A |
| Country | Spain | United States |
| Employees | 696 | 5 |
| Industry | Industrial Specialties | |
| Sector | Consumer Discretionary | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 53.4M | 54.7M |
| IPO Year | N/A | 2022 |
| Metric | WBX | GRML |
|---|---|---|
| Price | $2.75 | $0.44 |
| Analyst Decision | Buy | |
| Analyst Count | 4 | 0 |
| Target Price | ★ $4.75 | N/A |
| AVG Volume (30 Days) | 12.2K | ★ 3.3M |
| Earning Date | 05-06-2026 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $18.10 | N/A |
| Revenue Next Year | $94.11 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.23 | $0.27 |
| 52 Week High | $7.83 | $0.55 |
| Indicator | WBX | GRML |
|---|---|---|
| Relative Strength Index (RSI) | 41.47 | 50.60 |
| Support Level | $2.35 | $0.42 |
| Resistance Level | $3.27 | $0.53 |
| Average True Range (ATR) | 0.18 | 0.06 |
| MACD | -0.04 | -0.00 |
| Stochastic Oscillator | 12.86 | 30.41 |
Wallbox NV is a smart electric vehicle charging and energy management company. It creates a smart charging system combining technology design that manages the communication between the user, vehicle, grid, building, and charger. The company designs, manufactures, and distributes faster, simpler EV charging solutions for residential, business, and public use. Its smart charging product portfolio includes Level 2 alternating current chargers for home and business applications and direct current fast chargers for public applications. The company has three reportable operating segments: Europe, the Middle East and Asia (EMEA), its key revenue-generating segment, North America, and Asia-Pacific.
Greenland Mines Ltd develops essential medicines for the treatment of chronic diseases - cancer, cardiovascular, and neurodegenerative disorders. The Company operates as a single reporting segment focused on developing essential medicines for these chronic diseases. The Company has acquired two licensed platforms: a generic drug portfolio and a biosimilar biologics platform that uses biologic therapies to treat cancer, and proprietary patented technologies involving melanocortin receptor-binding molecules and a gene therapy platform that introduces a therapeutic protein called Klotho inside the body to treat neurodegenerative diseases.